ABUS vs BAC · P/E 5.4, rev $6.2M vs P/E 13, rev $113.10B
Arbutus Biopharma Corp (ABUS) versus Bank of America Corp (BAC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Bank of America Corp (BAC) is a banks - diversified company listed on US. It is led by Brian Moynihan.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BAC revenue for 2025-12-31 was $113.10B. Net income was $30.51B. Revenue was up 11.0% from 2024-12-31 to 2025-12-31. BAC currently screens at market cap $382.01B and trailing P/E 13.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BAC currently screens at market cap $382.01B and trailing P/E 13.4.
Not investment advice. Open the ABUS and BAC stock pages for the full models.
Not investment advice.